NT5E and cancer: Presently, all available preclinical data emphasize the worth of CD73 as a potential therapeutic target for cancer control [96,97], encouraging clinical studies aimed at evaluating the use of anti-CD73 MEDI9447 mAb and/or LY3475070 small inhibitor molecules alone or in combination with a PD-1 blockade in patients with advanced solid tumors [98].